In the search for an effective vaccine against the human pathogen, Listeria monocytogenes (Listeria), gold glyconanoparticles (GNP) loaded with a listeriolysin O peptide LLO 91-99 (GNP-LLO) were used to immunise mice, initially using a dendritic cell (DC) vaccine approach, but subsequently using a standard parenteral immunisation approach. To enhance vaccine immunogenicity a novel polysaccharide adjuvant based on delta inulin (Advax TM ) was also co-formulated with the GNP vaccine. Confirming previous results, DC loaded in vitro with GNP-LLO provided better protection against listeriosis than DC loaded in vitro using free LLO peptide. The immunogenicity of GNP-LLO loaded DC vaccines was further increased by addition of Advax TM adjuvant. However, as DC vaccines are expensive and impracticable for prophylactic use, we next asked whether the same GNP-LLO antigen could be used to directly target DC in vivo. Immunisation of mice with GNP-LLO plus Advax TM adjuvant induced LLO-specific T-cell immunity and protection against Listeria challenge. Protection correlated with an increased frequency of splenic CD4 + and CD8 + T cells, NK cells and CD8␣ + DC, and Th1 cytokine production (IL-12, IFN-␥, TNF-␣, and MCP-1), post-challenge. Enhanced T-cell epitope recruitment post-challenge was seen in the groups that received Advax TM adjuvant. Immunisation with GNP-LLO 91-99 plus Advax TM adjuvant provided equally robust Listeria protection as the best DC vaccine strategy but without the complexity and cost, making this a highly promising strategy for development of a prophylactic vaccine against listeriosis.
Introduction
Candidate prophylactic vaccines against Listeria monocytogenes (Listeria) include live attenuated pathogens [1] [2] [3] [4] , live vector-based Abbreviations: APC, antigen-presenting cells; CFU, colony forming units; Ctsd, cathepsin-D; DC, dendritic cells; GNP, gold glyconanoparticles; i.p, intra-peritoneal; i.v, intra-venous; LLO, listeriolysin O; MHC, major histocompatibility complex; MIIC, MHC-class II antigen loading compartments; MØ, macrophages; LM, Listeria monocytogenes. approaches [5] [6] [7] and subunit vaccines [8, 9] . However, the use of live vaccines in at-risk immunocompromised individuals including pregnant women poses major safety risks, making a non-living subunit vaccine a more preferable approach. Unfortunately, subunit vaccines by themselves are generally ineffective due to overall poor immunogenicity and inability, in particular, to generate the T-cell immunity required for protection against intracellular organisms such as Listeria.
Dendritic cell (DC) vaccines are produced by isolation of DC from a subject, in vitro loading of the DC with the relevant vaccine antigen, and then intravenous or subcutaneous injection of the live DC back into the subject. Based on their improved ability to induce T-cell immunity, DC vaccines have been proposed as solutions for induction of T-cell protection against intracellular infections, such as HIV [10] . Our group previously reported a DC vaccine loaded with a peptide from the Listeria protein, glyceraldehyde 3-phosphate http://dx.doi.org/10.1016/j.vaccine.2015.01.062 0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). dehydrogenase (GAPDH), induced generation of GAPDH-specific CD8 + and CD4 + T cells and conferred protection against Listeria [11] , consistent with the importance of T-cell responses against GAPDH in Listeria protection [12] [13] [14] . Other Listeria antigens that contain CD4 + and CD8 + T-cell epitopes and that might therefore enhance the efficacy of a DC-based Listeria vaccine include listeriolysin (LLO), ActA, and p60 [11, 15, 16] . To date, only T-cell immunity against LLO has been reported in humans recovering from listeriosis [17] , suggesting a potential role of in protection. We therefore wished to test whether a T-cell vaccine targeting LLO could protect against listeriosis. In particular, we sought to test whether a nanoparticleconjugated LLO peptide could increase DC vaccine efficacy [10, 18] and also whether a novel T-cell adjuvant could enhance LLO vaccine immunogenicity [19] . Gold glyconanoparticles (GNPs) constitute a nanoscale metallic core to which self-assembled monolayers of carbohydrate ligands are covalently linked by means of thiol chemistry [20] . Due to their water dispersibility, biocompatibility, resistance to enzymatic degradation, ease of preparation, and ability to incorporate different ligands, GNPs are highly versatile [21, 22] . In this study, therefore, we sought to test the potential of a glucose-labelled GNP presenting the LLO 91-99 peptide (GNP-LLO) to protect against listeriosis in a murine model. In the first approach, we sought to apply the previous approach of loading DC in vitro using the GNP-LLO carrier prior to injection of the DC back into the animals. However, given the logistical difficulties of the DC vaccine approach, we also wished to test whether, rather than being used for DC vaccine loading in vitro, the GNP-LLO antigen could be used for parenteral immunisation along the lines of a traditional vaccine.
Given the poor T-cell responses induced by subunit vaccines, we sought to further enhance GNP-LLO immunogenicity by use of Advax TM , a novel polysaccharide adjuvant derived from microparticles of delta ␤-d-[2-1]poly(fructo-furanosyl)␣-dglucose (delta inulin) [25] . In animal models Advax TM has been shown to enhance cellular plus humoral immunity against a broad spectrum of antigens including influenza [26] , Japanese encephalitis [27] , West Nile virus [28] , hepatitis B [29] , and HIV [30] vaccines. Advax TM has also been shown effective and safe in human trials of pandemic influenza [31] and hepatitis B [29] , vaccines.
Methods

Peptides and adjuvants
We used as immunogens, peptides representing known Listeria T cell epitopes, namely GAPDH 1-22 , LLO 91-99 and LLO 189-201 [6, 11, 15] . Immunisation with free LLO [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] peptides has previously been shown to induce CD4 + T cell responses in mice but did not confer Listeria protection [11, 32] . All peptides were synthesised at CNB, CSIC, Madrid followed by high performance liquid chromatography (HPLC) and mass spectrometry using a MALDI-TOF Reflex TM IV mass spectrometer (Bruker Daltonics, Bremen, Germany). Peptide purity was >95% after HPLC. Advax TM adjuvant (Adv1) was supplied by Vaxine (Adelaide, Australia) [31, [33] [34] [35] , and was mixed with antigen by simple admixture immediately before immunisation of mice.
Bacteria
L. monocytogenes 10403S strain (LM WT ) was obtained from D.A. Portnoy (University of California, Berkeley, CA, USA).
Preparation of gold glyconanoparticles bearing LLO 91-99 peptides (GNP-LLO 91-99 )
LLO 91-99 peptide with a C-terminal cysteamide (LLO 91-99 C(O) NHCH 2 CH 2 SH, 14 mg, purity 95%) was purchased from GenScript and 5-(mercapto)pentyl-␤-d-glucopyranoside (GlcC 5 SH) was prepared as reported in the literature [36] . GNP preparation is included in Supplemental information. Average gold diameter 1.5 ± 0.5 nm (the size histogram in Fig. S1 , panel A was obtained by counting 600 particles in the TEM image).
Preparation of DC vaccines
Bone-marrow DC were differentiated with GM-CSF, and CD11c + cells isolated with anti-mouse CD11c-coated magnetic beads and MACS separation columns (Miltenyi Biotech Inc., Auburn, CA) [6, 11] from 8 to 12 week-old female CD1, Balb/c or C57BL/6 mice. Bone marrow macrophages (DM) were obtained from same femurs and differentiated with M-CSF, as described [11] . DC used were MHC-II + CD11c + CD40 + CD11b +/− CD86 +/− F4/80 − Gr-1 − and of DM were CD11b + MHC-II + F4/80 +/− CD11c − Gr-1 − CD40 − CD86 − . Cultured DC were ex vivo loaded with 50 g/ml GAPDH 1-22 , LLO 91-99 or LLO 189-201 peptides or with 5 g/ml of GNP-LLO 91-99 for 24 h. Cells were analysed for apoptosis by FACS analysis using annexin-V-APC and H-1770 (BD-Biosciences), for cell viability with Trypan blue staining, and cell surface markers by FACS.
T-cell assays
T-cell analysis, cytotoxic T lymphocytes responses and delayed type hypersensitivity (DTH) analysis are described in Supplemental information.
Preparation of peptide-coupled GNP vaccines
GNP carrying approximately 90% glucose and 10% LLO 91-99 ( Fig.  S1 , panel A) were prepared by reduction in situ of Au(III) salt with sodium borohydride, as described [21, 37] . The ligands (LLO 91-99 peptide and glucose) were derivatised with thiol-ending linkers to attach them to the gold core ( Fig. S1 , panel A). 5-Mercaptopentyl ␤-d-glucopyranoside (GlcC 5 SH) with a short aliphatic linker, as previously reported [36] was used as a ligand partner to control the density of LLO 91-99 peptide on the GNPs. Glucose is ideal to confer water dispersibility and biocompatibility to the GNPs without interfering with the antigenic properties of LLO 91-99 peptide [24] . LLO peptides and GNP-LLO 91-99 did not adversely affect DC viability or promote apoptosis ( Fig. S1 , panel B and DC column in Table  S1 ). They were also well tolerated at 50 g/ml concentrations in C57BL/6, CD-1 or Balb/c mice strains, (C57BL/6 column in Table S1 ), while at 500 g/ml concentrations they caused decreased DC viability and increased IL-1 concentration suggesting potential toxicity (Table S1) [38] .
GNP immunogenicity assessment
We immunised mouse footpads with 0.1 g of recombinant LLO (LLO rec ) and then evaluated T-cell proliferative recall responses to in vitro stimulation with LLO 91-99 , LLO 189-201 , GNP-LLO 91-99 , LM WT lysate (LM-lysate) or LLO rec at doses ranging from 0 to 500 g/ml. Tcell proliferation was dose dependent peaking at 50 g/ml and then declining for all antigens (Fig. S1 , panel C). GNP-LLO 91-99 induced a high level of T-cell proliferation equivalent to LM-lysate ( Fig. S1 , panel C). LLO 91-99 and LLO rec induced the next best T-cell proliferation, while LLO 189-201 was lowest. To test whether the higher T-cell recall responses with GNP-LLO 91-99 might reflect improved MHC-I antigen processing by lymph node APC, we compared MHC-I peptide presentation after ex vivo loading of DC or DM with LLO 91-99 or GNP-LLO 91-99 . MHC-I molecules were immuno-precipitated and levels of LLO peptides bound to MHC-I assessed by western-blot using rabbit anti-LLO antibodies, as previously reported for MHC-II molecules [5, 11] . GNP-LLO 91-99 resulted in higher efficiency loading than free LLO 91-99 peptides of MHC-I molecules on either DC or DM ( Fig. S1 , panel D), with far higher presentation by DC than DM ( Fig. S1 , panel D).
Ex vivo activation of DC vaccines
We examined the effect of LLO peptide carriers on DC vaccine activation [6, 10] . Activated DC show a characteristic CD11c + MHC-II + CD40 + CD86 + phenotype [10, 18] . To examine DC activation by LLO carriers, at day 5 after GM-CSF differentiation, DC were purified as CD11c + cells using MACS magnetic beads (Miltenyi) and loaded ex vivo for 24 h with 5 g/ml of GNP-LLO 91-99 in presence or absence of Advax TM adjuvant (50 g/ml) or with 50 g/ml of LLO 91-99 , LLO 189-201 , LM-lysate or left untreated (DC-CONT). Next, the frequency of CD11c + MHC-II + cells positive for CD40 + or CD86 + DC was assessed as markers of mature and activated DC ( Fig. S2, panel A) . DC-Listeria lysate induced the highest frequency of MHC-II high DC followed by GNP-LLO 91-99 with or without Advax TM , which were both significantly higher than LLO 189-201 ( Fig.  S2, panel B) . A similar picture was seen for CD11c + MHC-II + CD40 + or CD11c + MHC-II + CD86 + DC. Differences between GNP loaded and free peptide were even more marked when we analysed the frequency of CD40 + CD86 + double positive DC ( Fig. S2 , panel C).
Immunisation
DC vaccines loaded in vitro using either free peptide or GNPconjugated peptides are indicated by placement of "DC" in front of the specific antigen. If the name of the vaccine does not contain "GNP" then this means DC loading or immunisation was done with free peptide. Vaccines used were either DC vaccines (DC-LLO 91-99 , DC-LLO 189-201 , DC-GAPDH 1-22 , DC-GNP-LLO 91-99 , all at doses of 1 × 10 6 DC per immunisation), or standard vaccines (GNP-LLO 91-99 at 5 g per immunisation). Standard vaccines were administered with or without Advax TM adjuvant (250 g per immunisation). Mice were immunised intra-peritoneally (i.p) (n = 5), intravenously in the tail vein (i.v) (n = 5) or left non-vaccinated (NV). Seven days after immunisation mice were challenged i.p or i.v with 5 × 10 3 CFU of Listeria microorganisms/mouse [2] . Sera were stored at −80 • C to measure cytokines by FACS analysis. At termination spleens and livers were homogenised and Listeria colony forming units (CFUs) counted in blood agar plates.
Frequencies of CD8 + -LLO 91-99 specific T cells
To confirm the frequency of IFN-␥ producing LLO 91-99 specific CD8T cells we used recombinant soluble dimeric mouse H-2K b :Ig (for C57BL/6 mice) or H-2K d :Ig (for Balb/c mice) fusion proteins following the manufacturer's instructions (DimerX I; BD Bioscience) and as previously described [2, 11] .
Ethics statement
This study was carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the Spanish Ministry of Science, Research and Innovation. The Committee on the Ethics of Animal Experiments of the University of Cantabria approved the protocol (Permit Number: 2012/06) that follows the Spanish legislation (RD 1201/2005). All surgery was performed under sodium pentobarbital anaesthesia, and all efforts were made to minimise suffering.
Statistical analysis
For statistical analysis, Student's t test was applied. ANOVA analysis was applied to cytokine measurements. P ≤ 0.05 was [14] . Results show the mean ± SD of the stimulation index calculated as ratio of proliferation in active wells/proliferation of control samples in triplicate (P < 0.05). (B) Mice were immunised i.p with 5 × 10 3 CFU of Listeria/mice and 7 days later DTH assays performed. Results are expressed as the mean difference± SD of footpad swelling at 24 and 48 h inactive and control limbs, representative example of three independent experiments (P < 0.05). considered significant. GraphPad software was used for generation of graphs.
Results
DC vaccines loaded using GNP-peptide carriers induce T-cell proliferative responses against Listeria
Dendritic cells stimulate both CD4 + and CD8 + T cells in listeriosis [14] . To evaluate whether dendritic cell (DC) vaccines loaded using GNP-peptide carriers might be more efficient in inducing T-cell responses than DC loaded using free peptides, mice were immunised with DC that had been loaded in different ways. Seven days post-immunisation, popliteal lymph nodes were stimulated in vitro with LLO 91-99 peptide and antigen-specific T-cell proliferative responses measured. Immunisation with DC loaded in vitro with GNP-LLO 91-99 induced higher T-cell proliferation responses than immunisation with DC loaded using free LLO 91-99 peptide, indicating the importance for induction of T-cell memory of attachment of the LLO 91-99 peptide to the GNP to enable efficient loading of DC vaccines. DC loaded in vitro with GNP-LLO 91-99 induced an equivalent T-cell proliferative response to a whole Listeria lysate, consistent with efficient DC loading and induction of T-cell responses by the GNP-peptide carrier (Fig. 1A) . DC loaded with a CD4 + restricted epitope (LLO 189-201 ) [11] , failed to induce a T-cell proliferative response, suggesting the DC vaccines preferentially induce a CD8 + T-cell response.
DC vaccines loaded using GNP-peptide carriers induce DTH responses in Listeria-sensitised mice
Next, we examined the delayed type hypersensitivity (DTH) response to the DC vaccines in previously Listeria-sensitised mice as an in vivo measure of the ability of the different DC vaccines to induce T-cell activation. The aim was to evaluate whether DC loaded in vitro with GNP-LLO 91-99 when injected into the footpad of previously sensitised mice would trigger a typical Th1-type T-cell response as measured by DTH [7] . We injected Listeria sensitised mice in the footpad with DC loaded in vitro with LLO 91-99 or LLO 189-201 free peptides or with GNP-LLO 91-99 . In fact, DC loaded with LLO 189-201 generated greater DTH responses in the sensitised mice than DC loaded with LLO 91-99 or GNP-LLO 91-99 , suggesting that LLO 189-201 is normally a dominant T-cell epitope after Listeria infection (Fig. 1B) . Interestingly, the DTH response to DC loaded with GNP-LLO 91-99 in the presence of Advax TM adjuvant was similar in size to the DC-LLO 189-201 response suggesting the LLO 91-99 epitope could be turned into a dominant epitope, providing it was presented by DC at a sufficiently high level together with sufficient co-stimulatory molecule expression induced by the Advax TM adjuvant (Fig. 1B) .
Immunisation with GNP-loaded DC vaccines provides protection of mice against listeriosis
We next assessed protection against listeriosis using the different DC vaccine vectors, DC-LLO 91-99 , DC-LLO 189-201 , DC-GAPDH 1-22 , DC-Listeria lysate, DC-GNP-LLO 91-99 , and empty DCs (DC-CONTROL) when compared to immunisation with free GNP-LLO 91-99 . DC-GAPDH 1-22 was included as a positive control since it previously showed good Listeria protection [11] . Mice were immunised i.v with a single dose of vaccine. Although i.v is an unusual immunisation route for standard vaccines, it is a typical route for administration of cellular DC vaccines [6] . Seven days postimmunisation the mice were administered a live Listeria challenge. Five days post-challenge, all mice were sacrificed and livers and spleens recovered to count Listeria colony forming units (CFU) and analyse the immune cell populations. DC-GAPDH 1-22 and DC-GNP-LLO 91-99 provided the greatest Listeria protection (∼97 and 99% CFU reduction, respectively), followed by DC-LLO 91-99 (∼94%) ( Fig. 2A) . DC-LLO 189-201 conferred no significant protection (5%). Notably, immunisation of mice with free GNP-LLO 91-99 (as opposed to DC pre-loaded in vitro with GNP-LLO 91-99 ) conferred intermediate protection (∼60% CFU reduction). Control non-vaccinated mice (NV) were not protected and as expected had enlarged spleens and granulomatous livers post-challenge ( Fig. 2A, right hand figure) .
Immunisation with GNP-loaded DCs increases the frequency of DC and CD8T cells in the spleen post-challenge
Protection in listeriosis is typically reflected by increases in the frequency of splenic macrophages (MØ), natural killer cells (NK), mature DC and activated T cells post Listeria challenge [14, 39] . We therefore examined the cell populations in the spleens of immunised mice 5 days post-challenge. Mice immunised with DC-LLO 91-99 , DC-GAPDH 1-22 , DC-GNP-LLO 91-99 or free GNP-LLO 91-99 particles showed an increased frequency of mature DC (70% of positive cells), CD8 + T cells (∼32% of positive cells), MØ (18-19% Table 1 Frequencies of LLO91-99-CD8 + T cells induced by DC vaccines. Splenocytes of vaccinated mice incubated with recombinant dimeric H-2K b :Ig fusion protein loaded with LLO91-99 peptide. Frequencies of CD8 + -LLO91-99 and IFN-␥ producers were performed as described in Section 2.1.10. Results are expressed as the mean ± SD (P < 0.05). 
Vaccination type
Listeria protection by GNP-loaded DC is associated with an enhanced Th1 T-cell response
We next evaluated whether Listeria protection of immunised mice was associated with enhanced Th1 cytokine production, as would be predicted for protection against an intracellular bacterium. Immunisation with DC-LLO 91-99 , DC-GAPDH 1-22 , DC-GNP-LLO 1-99 and, to a lesser extent, free GNP-LLO 91-99 was associated with high levels of MCP-1, TNF-␣ and IFN-␥ production, consistent with a strong Th1 response (Fig. 2C) . However, only DC-GAPDH 1-22 and DC-GNP-LLO 1-99 immunisation was associated with measurable IL-12 production, post-challenge, (Fig. 2C) , which correlated with these groups having the greatest Listeria protection ( Fig. 2A) [6, 11] . Next, we compared the ability of the different vaccines to induce LLO-specific T-cell immunity. DC-GNP-LLO 91-99 induced a higher frequency of LLO-specific IFN-␥ + CD8 + T cells (3.42%), than induced by DC-LLO 91-99 (1.22%), ( Table 1 ). The response induced by DC-GNP-LLO 91-99 thereby compared favourably to the 4.2% frequency of LLO-specific CD8 + T cells obtained with the most protective Listeria vaccine we had identified to date, DC-GAPDH 1-22 , [11] .
Advax TM adjuvant enhances Listeria protection by GNP-LLO 91-99
DC vaccines are expensive and impracticable. However, standard immunisation with free GNP-LLO 91-99 vaccine only provided intermediate levels of Listeria protection, (∼60% CFU reduction, Fig. 2 ), that was inferior to the protection obtained with the DC vaccines. We wished to test, therefore, whether formulation of GNP-LLO 91-99 with Advax TM adjuvant might enhance its ability to protect when administered through a traditional vaccine approach. Mice immunised i.p with a single dose of GNP-LLO 91-99 plus Advax TM did indeed exhibit enhanced protection (84%) when compared to mice immunised with GNP-LLO 91-99 alone (60%) (Fig. 3A) . This thereby achieved comparable levels of Listeria protection to those previously only achieved with the DC vaccine approach.
Analysis of spleen populations 5 days post-challenge confirmed that i.p immunisation with GNP-LLO 91-99 plus Advax TM adjuvant, induced a similar frequency of mature DC, CD8 + T cells and NK cells and a higher frequency of CD4 + T cells when compared to the DC vaccine, DC-GNP-LLO 91-99 (Fig. 3B ). This suggests that providing it was formulated with Advax TM adjuvant, standard immunisation with GNP-LLO 91-99 was as good or better at inducing T-cell responses and protection against Listeria than the much more complex DC vaccine approach. 3.7. Advax-adjuvanted GNP-LLO 91-99 increases splenic IL-12 + CD8˛+ DC post-challenge CD8␣ + DCs play a critical role in presentation of Listeria antigens to protective CD4 + and CD8 + T cells and, in particular, in IL-12 production that correlates with protection [39, 40] . We therefore analysed splenic DC content, post-challenge. The frequency of splenic CD8␣ + DC was almost doubled from 10% to 18% when GNP-LLO 91-99 was formulated with Advax TM adjuvant (Fig. 3C) . This contrasted with a low frequency (2-3%) of CD8␣ + DC in the spleen of non-vaccinated mice post-challenge. Notably, immunisation with free GNP-LLO 91-99 plus Advax TM adjuvant generated a higher frequency of splenic CD8␣ + DC than the DC vaccines (DC-GNP-LLO 91-99 or DC-LLO 91-99 ) (10%) (Fig. 3C) . Hence, when formulated with Advax TM adjuvant, standard immunisation with GNP-LLO 91-99 was as good or better than the more complex DC vaccine approach at inducing splenic CD8␣ + DC that play a critical role in listeria protection
Formulation of GNP-LLO 91-99 vaccine with Advax TM adjuvant enhances Th1 cytokine responses
Since formulation of vaccines with Advax TM increased the frequency of both CD8 + T cells and CD8␣ + DC in the spleen post-Listeria challenge, we next examined serum cytokine levels post-challenge in splenocytes of mice immunised with or without Advax TM adjuvant. Mice immunised with GNP-LLO 91-99 plus Advax TM exhibited significantly greater MCP-1, TNF-␣ and IFN-␥ production when compared to mice immunised with GNP-LLO 91-99 alone, consistent with Advax TM driving an enhanced Th1-response against Listeria. Cytokine levels in mice immunised with GNP-LLO 91-99 plus Advax TM were equivalent to those seen with the DC vaccine, DC-GNP-LLO 91-99 ( Fig. 3D, upper panel) . Immunisation with GNP-LLO 91-99 plus Advax TM was also associated with significantly greater splenocyte IL-12 and IL-10 production and reduced IL-6 production when compared to immunisation with GNP-LLO 91-99 alone (Fig. 3D, lower panel) , consistent with the Advax TM adjuvant enhancing the Th1 response against Listeria.
3.9. Formulation of GNP-LLO 91-99 with Advax TM adjuvant enhances IFN -producing Listeria-specific CD4 + and CD8 + T cells Next, we evaluated the effect of Advax TM on the ability of standard immunisations with GNP-LLO 91-99 to induce LLO-specific CD8 + and CD4 + T cells using IFN-␥ as a Th1 subset marker. Five days post Listeria challenge, mice immunised with GNP-LLO 91-99 alone had a detectable frequency (0.59%) of LLO 91-99 specific IFN-␥+ CD8 + T cells, but as expected had no responses against the CD4 + T cell epitope not contained in the vaccine (Fig. 3E, upper panel) . Immunisation with GNP-LLO 91-99 plus Advax TM not only resulted in a significant increase in the frequency of LLO 91-99 specific IFN-␥+ CD8 + T cells (0.89%) but also resulted in the appearance of a significant number of IFN-␥+ CD4 + T cells recognising the CD4 epitope, LLO [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] , not present in the vaccine (Fig. 3E, lower panel) . Thus the Advax adjuvant enhanced the ability of the Listeria vaccine to prime for a process of T-cell epitope spreading in response to Listeria infection.
To confirm the above findings, the ability of Advax TM when added to either DC vaccines or free GNP-LLO 91-99 vaccine to induce LLO 91-99 -specific CD8 + cells was tested using H2-K b -LLO 91-99 dimers to label and identify the antigen-specific T cells (H2-K d -LLO 91-99 dimers were used with similar results, data not shown).
Addition of Advax TM to GNP-LLO 91-99 resulted in a 4-fold increase in the frequency of LLO 91-99 -specific CD8 + cells versus GNP-LLO 91-99 vaccine alone, and was superior to all other vaccine formulations including the DC vaccine, DC-GNP-LLO 91-99 (Table 1 , left hand column). The effects of Advax TM were even more pronounced when H2-K b -LLO 91-99 positive cells were gated for IFN-␥, with ∼10fold higher frequency of IFN-␥ expressing H2-K b -LLO 91-99 positive cells in mice vaccinated with GNP-LLO 91-99 plus Advax versus mice vaccinated with free GNP-LLO 91-99 alone ( Table 1 , right hand column). This confirmed that providing the vaccine included Advax TM adjuvant, standard immunisation with GNP-LLO 91-99 was superior to all other vaccine approaches, including use of the best GNPloaded DC vaccine, at inducing Listeria-specific IFN-␥ + CD8 + T cells, the critical cells involved in protection.
Discussion
The objective of this study was to identify an optimal vaccine formulation to protect against listerosis. Listeria protection is largely dependent on CD4 + and CD8 + T cells rather than antibodymediated immunity [14, 17] . Live vector vaccines are inherently unsuitable for Listeria vaccines given their risk of causing serious infection in immune-compromised individuals. As an alternative, cellular DC-based vaccines where DC are loaded with Listeria antigens ex vivo [6, 11, 19] and injected back into the host have been proposed for induction of protective cellular immunity. We initially designed a DC vaccine based on loading of DC with LLO 91-99 peptide using conjugated GNP (GNP-LLO 91-99 ) and showed that this provided a high efficiency of DC loading, in vitro [22, 23] . DC-GNP-LLO 91-99 induced CD8 + T cell immunity in immunised mice that translated into protection against Listeria challenge. However DC vaccines are impractical and expensive to make, necessitating that we find an alternative strategy for delivery of our GNP-based vaccine. To overcome these problems, we next tested whether standard immunisation with GNP-LLO 91-99 rather than using it to load DC in vitro, could target and load DC in vivo. However, only partial protection was obtained by standard immunisation with free GNP-LLO 91-99 vaccine, inferior to that obtained with the DC vaccine. To overcome this problem, we next formulated the free GNP-LLO 91-99 antigen with Advax TM , a polysaccharide adjuvant shown effective and safe in a broad range of animal models and human trials [25] [26] [27] [28] [29] [30] [31] [33] [34] [35] . In addition to a strong human safety record, Advax TM was selected based on its ability to induce robust CD4 + and CD8 + T cell responses [30, 35] . As a proof of principle we first showed that Advax TM enhanced the immunogenicity of the DC vaccine, GNP-LLO 91-99 . This finding suggests Advax adjuvant may offer benefits for DC vaccines for other indications such as cancer, where the cost and complexity of DC vaccines is less an issue. However, given our desire to move away from the DC vaccine approach for Listeria, the most important finding was that Advax TM significantly enhanced the immunogenicity of GNP-LLO 91-99 when administered as a standard vaccine. Notably, this translated into improved Listeria protection to a level we had previously only achieved using DC vaccines. The enhanced protection obtained with the Advaxadjuvanted GNP-LLO 91-99 vaccine was associated with an increased frequency of splenic CD4 + and CD8 + T cells, NK cells and CD8␣ + DC. The latter have been reported to play a critical role in Listeria protection via ability to produce IL-12 and activate IFN-␥ producing CD4 + and CD8 + T cells [39, 40] . Notably, immunisation with Advax-adjuvanted GNP-LLO 91-99 enhanced production of the Th1 cytokines, IL-12, IFN-␥, TNF-␣, and MCP-1, while reducing the Th2 cytokine, IL-6. Interestingly, immunisation with Advax-adjuvanted were stimulated for 5 h with LLO91-99 or LLO189-201 peptides then intracellular cytokine staining performed. Histograms show the frequency of LLO189-201-specific CD4 + T cells and frequency of these making IFN-␥ producers (left plots) and the frequency of LLO91-99-specific CD8 + T cells and frequency of these making IFN-␥ (right plots). Experiments were performed in triplicate and results are expressed as mean ± SD (p < 0.05). GNP-LLO 91-99 was also associated with increased production of the anti-inflammatory cytokine, IL-10, but unlike other studies this increased IL-10 was not associated with enhanced Listeria susceptibility [32] . IL-10 may normally act as an inverse marker of IFN-␥ production as IL-10 is downregulated by IL-12 and IFN-␥ and vice versa. Because IL-12 and IFN-␥ are dominant in determining Listeria protection and were both markedly increased by Advax-adjuvanted GNP-LLO 91-99 , the IL-10 even although increased would not be expected to block IFN-␥-mediated protection in this situation, but may actually have been beneficial by reducing inflammatory damage in response to Listeria infection. Immunisation with Advaxadjuvanted GNP-LLO 91-99 resulted in an increased frequency of LLO 91-99 specific IFN-␥ + CD8 + T cells, post-challenge. More surprising was the increased frequency of LLO 189-201 specific IFN-␥ + CD4 + T cells, as this CD4 + epitope was not present in the vaccine the mice received so these CD4 + T cells must have been generated in response to the Listeria itself. This suggests that mice immunised with Advax TM adjuvant have a greater capacity for T-cell epitope spreading after Listeria challenge, thereby explaining the broader T-cell recognition of Listeria epitopes in the mice that received the Advax-adjuvanted GNP-LLO 91-99 vaccine.
Our model for how vaccination with Advax-adjuvanted GNP-LLO 91-99 provides enhanced protection against listeriosis is depicted in Fig. 4 . In brief, injection of soluble GNP-LLO 91-99 carriers (step 1) targets the conjugated peptide to conventional splenic DC that are stimulated to a mature phenotype and can then prime LLO 91-99 -specific CD8 + T cells (step 3). Upon exposure to Listeria (step 2), these CD8 + T cells become activated and produce IFN-␥ that in turn enhances DC IL-12 production and consequent NK cell activation. A Th1 feedback loop is generated, which assists the induction of inflammatory and activated DC and MØ that phagocytose and kill the bacteria (step 4). Advax TM adjuvant recruits and interacts with DC resulting in an increase in mature DC and, in particular, CD8␣ + DC, which after loading with GNP-conjugated LLO 91-99 , migrate to the splenic white zones where they become activated and induce expansion of LLO-specific CD4 + and CD8 + T cells (step 5). Upon exposure to Listeria, these LLO-specific CD8 + T cells become activated and induce high levels of IFN-␥, IL-12, MCP-1, and TNF-␣. These Th1 cytokines enhance Listeria phagocytosis and destruction, while increased IL-10 may help prevent excess inflammation (step 6). CD8 + T cells generated by the Advax-adjuvanted vaccine enhance epitope spreading by inducing DC to express additional Listeria epitopes, thereby allowing recruitment of additional CD4 + T cells able in response to these MHC-II epitopes. This promotes further expansion and activation of LLOspecific T cells including IFN-␥ producing LLO 189-201 -specific CD4 + T cells (step 7) that synergise with IFN-␥-producing CD8 + T cells in Listeria control.
Overall, these results support further development of GNPpeptide carriers together with Advax TM adjuvant as a vaccine platform with potential applicability to prophylactic immunisation against Listeria, plus other broader uses.
